Maximum Tolerate Dose

A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
J Randolph Hecht, Steven Raman, Daniel Y Sze, A Craig Lockhart, Rebecca A Moss, Kate Liu, Jeffrey Chou, Tony Reid

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P180; DOI: 10.1186/2051-1426-3-S2-P180
Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
Michael B Atkins, Shilpa Gupta, Toni K Choueiri, David F McDermott, Igor Puzanov, Jamal Tarazi, Stephen Keefe, Brad Rosbrook, Debasis Chakrabarti, Elizabeth R Plimack

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P353; DOI: 10.1186/2051-1426-3-S2-P353
A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
Trishna Goswami, Paola Canelos, Radhika Parikh

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P73; DOI: 10.1186/2051-1426-2-S3-P73
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
Kim Margolin, Hing C Wong, Chihiro Morishima, Liza Hernandez, Marc Ernstoff, Peter R Rhode, Thomas A Waldmann

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P79; DOI: 10.1186/2051-1426-2-S3-P79
Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells
Aung Naing, Pete Anderson, Sergei Guma, Hsuan-Chu Chien, Lacey MM McQuinn, Joshua P Hein, Ralph G Zinner, Eugenie S Kleinerman, Nancy Gordon

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P251; DOI: 10.1186/2051-1426-1-S1-P251

Log in using your username and password

Main menu

Log in using your username and password

You are here

Maximum Tolerate Dose